10x Genomics, Inc.
TXG
$14.01
-$0.27-1.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 644.47M | 624.66M | 610.79M | 629.74M | 631.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 644.47M | 624.66M | 610.79M | 629.74M | 631.73M |
| Cost of Revenue | 196.19M | 197.65M | 196.00M | 210.13M | 222.99M |
| Gross Profit | 448.28M | 427.01M | 414.78M | 419.61M | 408.75M |
| SG&A Expenses | 337.97M | 348.30M | 343.24M | 338.33M | 339.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 788.87M | 806.25M | 803.24M | 806.16M | 820.06M |
| Operating Income | -144.41M | -181.59M | -192.46M | -176.42M | -188.32M |
| Income Before Tax | -79.33M | -153.40M | -177.70M | -175.92M | -233.22M |
| Income Tax Expenses | 5.27M | 3.63M | 4.93M | 6.63M | 6.56M |
| Earnings from Continuing Operations | -84.60 | -157.04 | -182.63 | -182.55 | -239.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.60M | -157.04M | -182.63M | -182.55M | -239.78M |
| EBIT | -144.41M | -181.59M | -192.46M | -176.42M | -188.32M |
| EBITDA | -110.85M | -146.88M | -156.58M | -139.57M | -151.07M |
| EPS Basic | -0.70 | -1.30 | -1.52 | -1.53 | -2.02 |
| Normalized Basic EPS | -0.63 | -0.84 | -0.91 | -0.80 | -0.88 |
| EPS Diluted | -0.70 | -1.30 | -1.52 | -1.53 | -2.02 |
| Normalized Diluted EPS | -0.63 | -0.84 | -0.91 | -0.80 | -0.88 |
| Average Basic Shares Outstanding | 488.69M | 485.00M | 481.79M | 478.76M | 475.76M |
| Average Diluted Shares Outstanding | 489.45M | 485.00M | 481.79M | 478.76M | 475.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |